CLDX up +3.72% percent Today $CLDX High is at 18.58 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CLDX up +3.72% percent Today $CLDX High is at 18.58 and the Low 17.47 with current volume of 1,350,595.

Recent News posted below.

Celldex Therapeutics Inc CLDX other info.
http://investorshangout.com/Celldex-Therapeut...LDX-53702/

CLDX Celldex Therapeutics Inc Recent Headline News

Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 268.38 (-1.22), CLDX: 18.85 (+1.13), ABBV: 65.67 (-0.38)

Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST

CLDX: 18.85 (+1.13), ALXN: 193.48 (+1.11)

Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains
at The Street - Tue Nov 18, 10:47AM CST
Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 18.85 (+1.13)

Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.14 (-0.25), CLDX: 18.85 (+1.13), SRPT: 15.38 (-0.19)

Critical Alerts For Kinder Morgan, Celldex Therapeutics, Baker Hughes Inc., RF Micro Devices and SolarCity Released By InvestorsObserver
PR Newswire - Tue Nov 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, CLDX, BHI, RFMD and SCTY.
KMI: 40.83 (+0.42), SCTY: 54.86 (-0.78), CLDX: 18.85 (+1.13), RFMD: 13.61 (-0.14), BHI: 62.82 (-0.73)

Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 55.50 (-0.16), CLDX: 18.85 (+1.13), AMAG: 35.45 (+0.11), AFFX: 9.01 (-0.57)

Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 28.88% Rise
Comtex SmarTrend(R) - Mon Nov 17, 4:40PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.30 to a high of $19.48. Yesterday, the shares gained 28.9%, which took the trading range above the 3-day high of $15.27 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 18.85 (+1.13)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Celldex Therapeutics Is Down 14.6% (CLDX)
Comtex SmarTrend(R) - Mon Nov 17, 3:58PM CST
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report a loss of $0.33 on sales of $324.0 thousand. Celldex Therapeutics actually reported a loss of $0.31 per share on sales of $1.1 million, beating EPS estimates by $0.02 and beating revenue estimates by $0.8 million. Shares of Celldex Therapeutics have slipped from $16.58 to $14.16, representing a loss of 14.6%, since the company reported earnings 13 days ago.
CLDX: 18.85 (+1.13)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST

CADC: 5.18 (-0.25), ANV: 1.65 (-0.39), BONE: 3.11 (-0.05), WLH: 19.10 (-0.06), CLDX: 18.85 (+1.13), ENZY: 8.16 (-0.09), TGEN: 6.20 (-0.02), CHOP: 2.02 (-0.11), MSBF: 9.90 (-0.01), NVGN: 1.76 (-0.04), DWA: 22.50 (+0.02), WHX: 2.32 (-0.02), VYFC: 19.73 (-0.02), VGGL: 3.20 (-0.21), SNSS: 2.20 (+0.13), DNR: 9.94 (-0.07), MOBI: 5.57 (-0.32), VPCO: 1.58 (-0.01), FOLD: 6.75 (unch), ATEA: 1.45 (-0.01)

Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - Mon Nov 17, 10:02AM CST
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 18.85 (+1.13)

Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - Mon Nov 17, 9:28AM CST

CLDX: 18.85 (+1.13)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST

CADC: 5.18 (-0.25), INO: 9.60 (-0.26), CLDX: 18.85 (+1.13), HAL: 48.00 (-0.54), ROX: 1.64 (-0.14), SNSS: 2.20 (+0.13), DNR: 9.94 (-0.07), DWA: 22.50 (+0.02), GSAT: 2.62 (+0.07), CMGE: 25.49 (-0.67), FOLD: 6.75 (unch), BHI: 62.82 (-0.73)

Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:57AM CST

CLDX: 18.85 (+1.13)

Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.55 (-0.07), NAVB: 1.20 (unch), NVAX: 4.93 (-0.08), CLDX: 18.85 (+1.13), SNSS: 2.20 (+0.13)

Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST

CLDX: 18.85 (+1.13)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST

HK: 2.86 (-0.02), NTES: 100.41 (-1.49), CIG: 4.90 (+0.01), TSRO: 30.68 (-0.77), DDD: 35.35 (-0.02), CLDX: 18.85 (+1.13), SCMP: 11.71 (-0.34), BVN: 9.52 (-0.25), ABGB: 15.31 (+0.91), SSE: 10.27 (-0.13)

Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 18.85 (+1.13)

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 18.85 (+1.13)

Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.49 (-0.40), INCY: 71.60 (+1.96), CLDX: 18.85 (+1.13), NLNK: 31.75 (-0.91), GSK: 46.16 (-0.12), BMY: 58.62 (-0.08), SRNE: 4.00 (unch)

Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 6.13 (-0.10), CLDX: 18.85 (+1.13), ATHX: 1.45 (+0.06), NVS: 95.58 (unch)

Celldex Therapeutics Inc (CLDX) Stock Research Links

CLDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 34

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 140

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Early Home Care Signals Families Should Not Ignore

Updated Category News Views 63

A pill organizer sitting untouched can say more than a family conversation ever will. Jay Mann of Amada Senior Care in Richmond points to a hard truth in HelloNation's Nov. 20, 2026 article: the need for in-home support often arrives quietly, disguised as little breaks in routines that everybody would rather wave away. This is not a matter for armchair diagnosis, and...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 85

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 95

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 30

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading

Top 5 Most Recently Viewed Articles

Eric Trump Predicts Bitcoin Will Surpass $1 Million Soon

Updated Category News Views 163

Eric Trump Highlights Bitcoin's Growing Significance Eric Trump, the son of former U.S. President Donald Trump, has made headlines recently with his bold prediction about the future of Bitcoin. Speaking at a prominent Bitcoin conference, he stated that the global adoption of Bitcoin is not just a trend but an accelerating reality, embraced by governments, corporations,...

Continue Reading
Strathcona Resources Reports Robust Q2 2025 Performance Results

Updated Category News Views 210

Strathcona Resources' Strong Q2 2025 Financial Performance Strathcona Resources Ltd. (TSX: SCR) has recently shared impressive financial and operating results for the second quarter of 2025. This quarter marks a key period for the company as it also declared a quarterly dividend of $0.30 per common share, showing its commitment to returning value to shareholders. During...

Continue Reading
Empowering Vietnam Veterans: Allsup's Advocacy for Disability Claims

Updated Category News Views 264

Honoring Vietnam Veterans During National Observances As the nation pauses to honor Vietnam veterans, it's vital to recognize the challenges they face with VA disability benefits. Many veterans have spent years navigating a complex system to retain the recognition of service-related conditions, and organizations like Allsup are stepping up to aid them. With a commitment...

Continue Reading
Natural Gas Prices Drop While Consumers Energy Supports Families

Updated Category News Views 145

Natural Gas Prices Decline for Families This Winter As winter chills spread across the region, Consumers Energy is doing its part to ensure customers benefit from lower natural gas prices. The company is adept at planning ahead to manage energy costs effectively. Energy Efficiency Through Smart Planning Consumers Energy has optimized its strategies by purchasing natural...

Continue Reading
CrossCountry Mortgage Dominates Emerging Stars Recognition

Updated Category News Views 226

CrossCountry Mortgage Leads Industry Recognition CrossCountry Mortgage (CCM) has established itself as the foremost retail mortgage lender in the nation. Recently, it emerged at the top of the prestigious Scotsman Guide Emerging Stars list. This recognition highlights the impressive number of loan officers associated with CCM, showcasing their dedication and...

Continue Reading